Savara’s Molbreevi BLA for autoimmune PAP was rejected by the FDA due to incomplete CMC data; the company plans to resubmit in Q4 2025.
Why Is Rare Lung Disease-Focused Savara Stock Trading Lower On Tuesday?
Where Today's News Shapes Tomorrow
March 26, 2026
Headlines
